Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial

AIMS/INTRODUCTION: Our aims were to examine the add‐on effects of a sodium–glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator, fibroblast growth factor 21 (FGF21); a skeletal m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamakage, Hajime, Tanaka, Masashi, Inoue, Takayuki, Odori, Shinji, Kusakabe, Toru, Satoh‐Asahara, Noriko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232283/
https://www.ncbi.nlm.nih.gov/pubmed/31721467
http://dx.doi.org/10.1111/jdi.13179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232283/
https://www.ncbi.nlm.nih.gov/pubmed/31721467
http://dx.doi.org/10.1111/jdi.13179

Ejemplares similares